Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.
Apimeds Pharmaceuticals US, Inc. (APUS) - Total Liabilities
Latest total liabilities as of September 2025: $1.09 Million USD
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has total liabilities worth $1.09 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Apimeds Pharmaceuticals US, Inc. - Total Liabilities Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Apimeds Pharmaceuticals US, Inc. Competitors by Total Liabilities
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Antler Gold Inc
V:ANTL
|
Canada | CA$1.50 Million |
|
Toyo Ventures Holdings Bhd
KLSE:7173
|
Malaysia | RM214.75 Million |
|
In-Touch Survey Systems Ltd.
V:INX
|
Canada | CA$5.01 Million |
|
TomaGold Corporation
PINK:TOGOF
|
USA | $1.81 Million |
|
Energy Development Company Limited
NSE:ENERGYDEV
|
India | ₹1.88 Billion |
|
KYM Holdings Bhd
KLSE:8362
|
Malaysia | RM41.08 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Apimeds Pharmaceuticals US, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Apimeds Pharmaceuticals US, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the annual total liabilities of Apimeds Pharmaceuticals US, Inc. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.37 Million | +251.40% |
| 2023-12-31 | $390.20K | -45.79% |
| 2022-12-31 | $719.78K | +75.28% |
| 2021-12-31 | $410.65K | -- |